Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  01:00:00 2023-02-02 am EST
3296.00 JPY   -0.87%
02:40aChugai Pharmaceutical : Full Year Results (Jan-Dec 2022)
PU
02/01Chugai Pharmaceutical : Hemlibra Approved by the European Commission to Treat People with Moderate Hemophilia
PU
01/17Japan's Nikkei rises as investors brace for BOJ decision
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
01/27/2023 01/30/2023 01/31/2023 02/01/2023 02/02/2023 Date
3444(c) 3392(c) 3358(c) 3325(c) 3296 Last
1 726 100 1 919 400 1 731 900 2 220 000 2 377 400 Volume
-1.20% -1.51% -1.00% -0.98% -0.87% Change
More quotes
Estimated financial data (e)
Sales 2022 1 197 B 9 254 M 9 254 M
Net income 2022 352 B 2 721 M 2 721 M
Net cash position 2022 532 B 4 115 M 4 115 M
P/E ratio 2022 15,5x
Yield 2022 2,39%
Sales 2023 1 041 B 8 051 M 8 051 M
Net income 2023 313 B 2 417 M 2 417 M
Net cash position 2023 753 B 5 825 M 5 825 M
P/E ratio 2023 17,5x
Yield 2023 2,52%
Capitalization 5 470 B 42 302 M 42 302 M
EV / Sales 2022 4,13x
EV / Sales 2023 4,53x
Nbr of Employees 7 664
Free-Float 38,0%
More Financials
Company
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%). 
Read more
Sector
Pharmaceuticals
Calendar
02/02 | 02:30amEarnings Release
More about the company
Ratings of Chugai Pharmaceutical Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD
02:40aChugai Pharmaceutical : Full Year Results (Jan-Dec 2022)
PU
02/01Chugai Pharmaceutical : Hemlibra Approved by the European Commission to Treat People with ..
PU
01/17Japan's Nikkei rises as investors brace for BOJ decision
RE
2022Japan's Nikkei ends flat, posts first annual loss in 4 years
RE
2022Japanese shares track Wall Street rise, caution ahead of holiday caps gains
RE
2022CHUGAI PHARMACEUTICAL CO., LTD : Ex-dividend day for fina..
FA
2022Chugai Pharmaceutical : The Launch of Chugai's New TV Commercial Featuring Tori Matsuzaka ..
PU
2022CHMP Recommends Expansion of EU Label for Hemlibra to Include People with Moderate Hemo..
AQ
2022CHMP recommends expansion of EU label for Hemlibra to include people with moderate haem..
AQ
2022Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningf..
AQ
2022Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment
AQ
2022Chugai Pharmaceutical Co., Ltd. - Transfer and Future Marketing of Osteoporosis Agent B..
AQ
2022Taisho Pharmaceutical Holdings Co., Ltd. (TSE:4581)..
CI
2022Chugai Pharmaceutical Co., Ltd. - Organizational and Personnel Changes
AQ
2022Chugai Pharmaceutical : Organizational and Personnel Changes
PU
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD
01/18El Nikkei sube un 2,5%, después de que el BOJ mantenga el control de los rendimientos -..
2022Le bénéfice net de Chugai Pharmaceutical pour les neuf mois de l'exercice 22 augmente d..
2022Nikkei 225 en hausse de 1 % alors que la saison des résultats commence
2022Chugai Pharmaceutical Co., Ltd. fournit des indications sur le dividende pour l'année s..
2022Chugai Pharmaceutical Co., Ltd. fournit des prévisions de bénéfices consolidés pour l'e..
More news
ETFs positioned on CHUGAI PHARMACEUTICAL CO., LTDETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Nomura NEXT FUNDS TOPIX-17 PHARMACEUTICAL E...7.05%-3.17%-Japan
Global X Longevity Thematic ETF - USD2.83%0.27%World
VanEck Global Healthcare Leaders ETF - AUD2.19%-1.73%-NC
Nomura NEXT FUNDS MSCI Japan Empowering Wom...1.87%-0.55%-NC
Daiwa ETF MSCI Japan Empowering Women Index - JPY1.83%3.28%-NC
More ETFs positioned on CHUGAI PHARMACEUTICAL CO., LTD
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 325,00 JPY
Average target price 4 339,23 JPY
Spread / Average Target 30,5%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-1.28%42 302
JOHNSON & JOHNSON-6.64%427 259
ELI LILLY AND COMPANY-5.93%327 004
NOVO NORDISK A/S0.53%310 851
ROCHE HOLDING AG-1.81%274 452
MERCK & CO., INC.-3.58%272 327